<SEC-DOCUMENT>0001140361-25-004784.txt : 20250214
<SEC-HEADER>0001140361-25-004784.hdr.sgml : 20250214
<ACCEPTANCE-DATETIME>20250214161023
ACCESSION NUMBER:		0001140361-25-004784
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250214
DATE AS OF CHANGE:		20250214

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Celularity Inc
		CENTRAL INDEX KEY:			0001752828
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				831702591
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-91021
		FILM NUMBER:		25628645

	BUSINESS ADDRESS:	
		STREET 1:		170 PARK AVE
		CITY:			FLORHAM PARK
		STATE:			NJ
		ZIP:			07932
		BUSINESS PHONE:		(908) 768-2170

	MAIL ADDRESS:	
		STREET 1:		170 PARK AVE
		CITY:			FLORHAM PARK
		STATE:			NJ
		ZIP:			07932

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GX Acquisition Corp.
		DATE OF NAME CHANGE:	20180912

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BRISTOL MYERS SQUIBB CO
		CENTRAL INDEX KEY:			0000014272
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				220790350
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	BUSINESS ADDRESS:	
		STREET 1:		ROUTE 206 AND PROVINCE LINE ROAD
		CITY:			PRINCETON
		STATE:			NJ
		ZIP:			08543
		BUSINESS PHONE:		6092524621

	MAIL ADDRESS:	
		STREET 1:		ROUTE 206 AND PROVINCE LINE ROAD
		CITY:			PRINCETON
		STATE:			NJ
		ZIP:			08543

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BRISTOL MYERS CO
		DATE OF NAME CHANGE:	19891012
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
<headerData>
<submissionType>SCHEDULE 13G/A</submissionType>
<previousAccessionNumber>0001140361-21-025628</previousAccessionNumber>
<filerInfo>
<filer>
<filerCredentials>
<cik>0000014272</cik>
<ccc>XXXXXXXX</ccc>
</filerCredentials>
</filer>
<liveTestFlag>LIVE</liveTestFlag>



</filerInfo>
</headerData>
<formData>
<coverPageHeader>
<amendmentNo>1</amendmentNo>
<securitiesClassTitle>Class A Common stock, par value $0.0001 per share</securitiesClassTitle>
<eventDateRequiresFilingThisStatement>12/31/2024</eventDateRequiresFilingThisStatement>
<issuerInfo>
<issuerCik>0001752828</issuerCik>
<issuerName>Celularity Inc</issuerName>
<issuerCusip>151190105</issuerCusip>
<issuerPrincipalExecutiveOfficeAddress>
<com:street1>170 Park Avenue</com:street1>
<com:city>Florham Park</com:city>
<com:stateOrCountry>NJ</com:stateOrCountry>
<com:zipCode>07932</com:zipCode>
</issuerPrincipalExecutiveOfficeAddress>
</issuerInfo>
<designateRulesPursuantThisScheduleFiled>
<designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
</designateRulesPursuantThisScheduleFiled>
</coverPageHeader>
<coverPageHeaderReportingPersonDetails>

<reportingPersonName>BRISTOL MYERS SQUIBB CO</reportingPersonName>
<citizenshipOrOrganization>DE</citizenshipOrOrganization>
<reportingPersonBeneficiallyOwnedNumberOfShares>
<soleVotingPower>0</soleVotingPower>
<sharedVotingPower>426372</sharedVotingPower>
<soleDispositivePower>0</soleDispositivePower>
<sharedDispositivePower>426372</sharedDispositivePower>
</reportingPersonBeneficiallyOwnedNumberOfShares>
<reportingPersonBeneficiallyOwnedAggregateNumberOfShares>426372</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
<aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
<classPercent>1.9</classPercent>
<typeOfReportingPerson>CO</typeOfReportingPerson>
<comments>(1) Calculated based upon 22,484,239 shares of Class A common stock, par value $0.0001 per share, outstanding as of December 2, 2024, as reported on the Issuer's Form 10-Q filed with the Securities and Exchange Commission on December 6, 2024.</comments>
</coverPageHeaderReportingPersonDetails>
<coverPageHeaderReportingPersonDetails>

<reportingPersonName>CELGENE CORPORATION</reportingPersonName>
<citizenshipOrOrganization>DE</citizenshipOrOrganization>
<reportingPersonBeneficiallyOwnedNumberOfShares>
<soleVotingPower>0</soleVotingPower>
<sharedVotingPower>426372</sharedVotingPower>
<soleDispositivePower>0</soleDispositivePower>
<sharedDispositivePower>426372</sharedDispositivePower>
</reportingPersonBeneficiallyOwnedNumberOfShares>
<reportingPersonBeneficiallyOwnedAggregateNumberOfShares>426372</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
<aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
<classPercent>1.9</classPercent>
<typeOfReportingPerson>CO</typeOfReportingPerson>
<comments>(1) Calculated based upon 22,484,239 shares of common stock, par value $0.0001 per share, outstanding as of December 2, 2024, as reported on the Issuer's Form 10-Q filed with the Securities and Exchange Commission on December 6, 2024.</comments>
</coverPageHeaderReportingPersonDetails>
<items>
<item1>
<issuerName>Celularity Inc</issuerName>
<issuerPrincipalExecutiveOfficeAddress>170 Park Avenue, Florham Park, New Jersey, 07932</issuerPrincipalExecutiveOfficeAddress>
</item1>
<item2>
<filingPersonName>This statement on Schedule 13G is being jointly filed by: (i) Bristol-Myers Squibb Company ("BMS") and (ii) Celgene Corporation ("Celgene"). Celgene is a direct wholly owned subsidiary of BMS.</filingPersonName>
<principalBusinessOfficeOrResidenceAddress>BMS
Route 206 &amp; Province Line Road, Princeton, New Jersey 08543

Celgene
86 Morris Avenue
Summit, New Jersey 07901</principalBusinessOfficeOrResidenceAddress>
<citizenship>Delaware</citizenship>
</item2>
<item3>
<notApplicableFlag>Y</notApplicableFlag>
</item3>
<item4>
<amountBeneficiallyOwned>See responses to Item 9 on each cover page.

Celgene, a direct wholly owned subsidiary of BMS, is the record holder of 426,372 shares of Class A Common Stock of the Issuer. BMS does not directly own any shares of Class A Common Stock of the Issuer. By reason of the provisions of Rule 13d-3 under the Act, BMS is deemed to own beneficially the Class A Common Stock that Celgene owns as a record holder.</amountBeneficiallyOwned>
<classPercent>See responses to Item 11 on each cover page.</classPercent>
<numberOfSharesPersonHas>
<solePowerOrDirectToVote>See responses to Item 5 on each cover page.</solePowerOrDirectToVote>
<sharedPowerOrDirectToVote>See responses to Item 6 on each cover page.</sharedPowerOrDirectToVote>
<solePowerOrDirectToDispose>See responses to Item 7 on each cover page.</solePowerOrDirectToDispose>
<sharedPowerOrDirectToDispose>See responses to Item 8 on each cover page.</sharedPowerOrDirectToDispose>
</numberOfSharesPersonHas>
</item4>
<item5>
<notApplicableFlag>N</notApplicableFlag>
<classOwnership5PercentOrLess>Y</classOwnership5PercentOrLess>
</item5>
<item6>
<notApplicableFlag>Y</notApplicableFlag>
</item6>
<item7>
<notApplicableFlag>Y</notApplicableFlag>
</item7>
<item8>
<notApplicableFlag>Y</notApplicableFlag>
</item8>
<item9>
<notApplicableFlag>Y</notApplicableFlag>
</item9>
<item10>
<notApplicableFlag>N</notApplicableFlag>
<certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
</item10>
</items>
<exhibitInfo>99.1     Joint Filing Agreement dated July 26, 2021, between BMS and Celgene.
https://www.sec.gov/Archives/edgar/data/14272/000114036121025628/brhc10027143_ex99-1.htm</exhibitInfo>
<signatureInformation>
<reportingPersonName>BRISTOL MYERS SQUIBB CO</reportingPersonName>
<signatureDetails>
<signature>/s/ Amy Fallone</signature>
<title>Amy Fallone / Corporate Secretary</title>
<date>02/14/2025</date>
</signatureDetails>
</signatureInformation>
<signatureInformation>
<reportingPersonName>CELGENE CORPORATION</reportingPersonName>
<signatureDetails>
<signature>/s/ Amy Fallone</signature>
<title>Amy Fallone / Vice President and Secretary</title>
<date>02/14/2025</date>
</signatureDetails>
</signatureInformation>
</formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
